Reteplase — CAS 133652-38-7

Reteplase is a high-purity Active Pharmaceutical Ingredient (API) classified under Thrombolytic / Fibrinolytic Agent. Mediocon Inc manufactures GMP-compliant Reteplase at its state-of-the-art facility in Aurangabad, Maharashtra, India, supplying pharmaceutical companies worldwide with consistent quality and full regulatory documentation.

• Acute myocardial infarction (AMI) thrombolysis
• Pulmonary embolism treatment
• Peripheral arterial thrombosis
• Cardiac catheterisation adjunct therapy

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / EP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support